Tuesday, December 4, 2012

• Forest Files Cariprazine NDAZacks (Tue, Dec 4)

Monday, December 3, 2012

• Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American College of Neuropsychopharmacology (ACNP) Annual MeetingBusiness Wire (Mon, Dec 3)
• How Should You Be Playing Forest Laboratories?at Motley Fool (Mon, Dec 3)

Friday, November 30, 2012

• Forest Rises On Unusually High Volume (FRX)at TheStreet (Fri, Nov 30)
• EU Approval for Ironwood's ConstellaZacks (Fri, Nov 30)

Thursday, November 29, 2012

• 3 Undervalued Healthcare Stocks Being Sold By Hedge Fundsat Seeking Alpha (Thu, Nov 29)

Wednesday, November 28, 2012

• Forest Laboratories, Inc. Announces Additional Settlement Agreements in BYSTOLIC® Patent LitigationBusiness Wire (Wed, Nov 28)
• 3 Attractive Stocks in BioPharma To Buyat Motley Fool (Wed, Nov 28)
• Forest Labs submits cariprazine for FDA reviewAP (Wed, Nov 28)
• Richter Rebounds From 6-Month Low on FDA Bid: Budapest Moverat Bloomberg (Wed, Nov 28)
• Forest Laboratories Submits New Drug Application for Cariprazine for the Treatment of Both Schizophrenia and Manic or Mixed Episodes Associated with Bipolar I DisorderBusiness Wire (Wed, Nov 28)

Sunday, November 25, 2012

• Here's What Billionaire Value Hunter Carl Icahn Is Buyingat Motley Fool (Sun, Nov 25)

Wednesday, November 21, 2012

• Billionaire Icahn’s Latest Stock Playsat Motley Fool (Wed, Nov 21)
• Pfizer's Lyrica Scores in StudyZacks (Wed, Nov 21)

Tuesday, November 20, 2012

• Forest Laboratories Inc. Stock Downgraded (FRX)at TheStreet (Tue, Nov 20)

Monday, November 19, 2012

• Data on Pfizer's LyricaZacks (Mon, Nov 19)

Friday, November 16, 2012

• 1 Great Dividend You Can Buy Right Nowat Motley Fool (Fri, Nov 16)

Thursday, November 15, 2012

• Forest Inks Alzheimer's Drug DealZacks (Thu, Nov 15)

Wednesday, November 14, 2012

• Synergy Pharma shoots higher on plecanatide plansAP (Wed, Nov 14)
• Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s DiseaseBusiness Wire (Wed, Nov 14)

Monday, November 12, 2012

• For NovaBay, Simplicity Is The Father Of Inventionat Seeking Alpha (Mon, Nov 12)

Friday, November 9, 2012

• FOREST LABORATORIES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri, Nov 9)
• Cubist Pharma Initiated at Neutral and 2 Initiated Shares on the Moveat Wall St. Cheat Sheet (Fri, Nov 9)
• New Stock Coverage: Forest Labs Looks Like a Money Treeat Minyanville (Fri, Nov 9)
• Forest Labs initiated with a Buy at Mizuhoat theflyonthewall.com (Fri, Nov 9)

Add FRX News to My Yahoo!